Category: imidazoles-derivatives

Bendamustine treatment of haematological malignancies: significant risks of opportunistic viral, fungal and bacterial infections was written by Wu, Tony K. Y.;Tang, Karen H. K.;Hwang, Yu-Yan;Chan, Thomas S. Y.;Tse, Eric;Kwong, Yok-Lam. And the article was included in Hematology (Abingdon, United Kingdom) in 2022.Product Details of 16506-27-7 The following contents are mentioned in the article:

Bendamustine is a standard treatment for low-grade B-cell lymphomas, and considered safe in clin. trials. Its safety in routine practice might be different. We retrospectively analyzed the infection complications in an unselected cohort of patients treated with bendamustine over a nine-year period. Patients were regularly monitored for blood counts and cytomegalovirus (CMV) reactivation by antigen assay and polymerase chain reaction. They received granulocyte colony stimulating factor for neutropenia, and routine anti-pneumocystis and optional anti-fungal prophylaxis. There were 179 men and 127 women at a median age of 61.5 (20-90) years, 52% receiving bendamustine for relapsed/refractory disease. Malignancies included low-grade B-cell lymphomas (54%), myeloma (10%), T-cell lymphomas (11%), Hodgkin lymphoma (2%) and other lymphoid neoplasms (23%). Most patients had good performance status (Eastern Cooperative Oncol. Group score: 0-1, 72%). CMV reactivation occurred in 58 patients (19%) at a median age of 68 (39-85) years. Univariate anal. showed CMV reactivation to be significantly associated with elevated lactate dehydrogenase (P = 0.045), decreased albumin (P = 0.003) and older age (reactivation vs. no reactivation: 66.3 ± 11.4 vs. 59.4 ± 14.5 years, P = 0.0016). Age remained the only significant risk on multivariate anal. CMV reactivation resulted in retinitis (N = 4), ependymitis/ventriculitis (N = 1) and duodenitis/colitis (N = 1). Invasive fungal disease occurred in five patients (candidemia, N = 2; aspergillosis N = 1; cryptococcemia, N = 1; scedosporiosis, N-1). Nineteen patients had culture pos. septicemia. Our observations showed that even with a vigorous anti-infective strategy, bendamustine treatment was still associated with significant risks of bacterial and opportunistic viral and fungal infections. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Product Details of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.Product Details of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Syntheses, structures and fluorescent properties of cadmium coordination polymers based on 2,3′,5,5′-biphenyl tetracarboxylate and N-donor ancillary ligands was written by Chang, Xin-Hong;Zhao, Ying;Feng, Xun;Ma, Lu-Fang;Wang, Li-Ya. And the article was included in Polyhedron in 2014.Product Details of 1374155-84-6 The following contents are mentioned in the article:

Self-assembly of cadmium(II) salt based on 2,3′,5,5′-biphenyl tetracarboxylate with or without various N-donor ligands affords a series of coordination polymers, namely {[Cd_1.5(Hbptc)(H₂O)_4.5]·2H₂O}_n (1), {[Cd₂(bptc)(2,2′-bipy)₂]·2H₂O}_n (2), {[Cd₂(bptc)(pyp)₂(H₂O)₂]}_n (3), [Cd(H₃bptc)₂(bip)₂]_n (4), and {[Cd₂(bptc)(bpt)(H₂O)]·H₂O}_n (5), where H₄bptc = 2,3′,5,5′-biphenyl tetracarboxylic acid, 2,2′-bipy = 2,2′-bipyridine, pyp = 3-(pyridin-2-yl)pyrazole, bip = 3,5-bis(1-imidazol)pyridine, bpt = 2-[3-(4-pyridinyl)-1H-1,2,4-triazol-5-yl]pyrazine. Their structures were determined by single-crystal x-ray diffraction anal. and further characterized by elemental anal. and IR spectra. Complex 1 shows a 2D helical layer, which is further extended to a 3D supermol. network through inter-layer C-H···O hydrogen bonds and π···π stacking interactions. Complex 2 exhibits a (3,6)-connected (4³)₂(4⁶.6⁶.8³)-kgd topol. Complex 3 possesses a 2D (3,5)-connected (4.5.6)(4.5³.6⁴.7²) net based on 1D tube-like chains. Complex 4 has a 1D polymeric ribbon containing left- and right-handed helical chains, which are further hydrogen bonded to form a 2D supermol. layer. Complex 5 possesses a 3D (4,5,7)-connected framework. Moreover, the fluorescent properties of 1–5 in the solid state have been investigated. This study involved multiple reactions and reactants, such as 3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6Product Details of 1374155-84-6).

3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Product Details of 1374155-84-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Effect of anti-reflux treatment on gastroesophageal reflux-associated chronic cough: Implications of neurogenic and neutrophilic inflammation. was written by Takeda, Norihisa;Takemura, Masaya;Kanemitsu, Yoshihiro;Hijikata, Hisatoshi;Fukumitsu, Kensuke;Asano, Takamitsu;Yamaba, Yusuke;Suzuki, Motohiko;Kubota, Eiji;Kamiya, Takeshi;Ueda, Takashi;Niimi, Akio. And the article was included in The Journal of asthma in 2020.Safety of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide The following contents are mentioned in the article:

Objective: Gastroesophageal reflux disease (GERD) is an important cause of chronic cough. Substance P (SP) has been implicated in the pathophysiology of cough. Proton pump inhibitors (PPIs) and prokinetic agents are the current treatment for GER-associated cough. The aim was to evaluate the effects of anti-reflux treatment and its associations with cellular and neurogenic inflammation.Methods: Thirty-seven patients with GER-associated cough suspected based on characteristic symptoms such as heartburn and worsening of cough by phonation and rising were recruited. A PPI, rabeprazole 20 mg daily, and a prokinetic agent, itopride 50 mg t.i.d., were administered for 4 weeks in a prospective, observational manner. Before and after treatment, subjective cough measures [visual analog scale (VAS) and the Japanese version of the Leicester Cough Questionnaire (J-LCQ)], the modified frequency scale for the symptoms of GERD [FSSG, consisting of 2 domains: acid-reflux (AR) and functional dyspepsia symptoms], sputum and plasma SP levels, and sputum cell differentials were examined. Patients with good response to treatment [Δ (decrease of) VAS >15 mm; n = 21) were compared with poor responders (ΔVAS ≤15 mm).Results: Anti-reflux treatment significantly improved the cough VAS, J-LCQ, and AR symptoms, and ΔVAS and ΔAR were significantly correlated. Decreases of plasma and sputum SP levels and sputum neutrophil counts were significantly greater in responders than in poor responders. Both baseline values and post-treatment changes of plasma SP and sputum neutrophils were significantly correlated for all patients.Conclusions: Successful treatment of GER-associated cough may be associated with the attenuation of neurogenic and neutrophilic inflammation. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Safety of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Safety of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review was written by Yasuda, Hajime;Yasuda, Mutsuko;Komatsu, Norio. And the article was included in Cancer Science in 2021.Safety of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

A review. Chemotherapy for non-Hodgkin lymphoma (NHL) in the hemodialysis (HD) patient is a challenging situation. Because many drugs are predominantly eliminated by the kidneys, chemotherapy in the HD patient requires special considerations concerning dose adjustments to avoid overdose and toxicities. Conversely, some drugs are removed by HD and may expose the patient to undertreatment, therefore the timing of drug administration in relation to HD sessions must be carefully planned. Also, the metabolites of some drugs show different toxicities and dialysability as compared with the parent drug, therefore this must also be catered for. However, the pharmacokinetics of many chemotherapeutics and their metabolites in HD patients are unknown, and the fact that NHL patients are often treated with distinct multiagent chemotherapy regimens makes the situation more complicated. In a realm where uncertainty prevails, case reports and case series reporting on actual treatment and outcomes are extremely valuable and can aid physicians in decision making from drug selection to dosing. We carried out an exhaustive review of the literature and adopted 48 manuscripts consisting of 66 HD patients undergoing 71 chemotherapy regimens for NHL, summarized the data, and provide recommendations concerning dose adjustments and timing of administration for individual chemotherapeutics where possible. The chemotherapy regimens studied in this review include, but are not limited to, rituximab, cyclophosphamide + vincristine + prednisolone, and cyclophosphamide + doxorubicin + vincristine + prednisolone-like regimens, chlorambucil, ibrutinib, bendamustine, methotrexate, platinum compounds, cytarabine, gemcitabine, etoposide, ifosfamide, melphalan, busulfan, fludarabine, mogamulizumab, brentuximab vedotin, and 90Y-ibritumomab tiuxetan. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Safety of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Safety of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Prognostic model of eleven genes based on the immune microenvironment in patients with thymoma was written by Yang, Ying;Xie, Liqing;Li, Chen;Liu, Liangle;Ye, Xiuzhi;Han, Jianbang. And the article was included in Frontiers in Genetics in 2022.Recommanded Product: 16506-27-7 The following contents are mentioned in the article:

The pathogenesis of thymoma (THYM) remains unclear, and there is no uniform measurement standard for the complexity of THYM derived from different thymic epithelial cells. Consequently, it is necessary to develop novel biomarkers of prognosis estimation for patients with THYM. Consensus clustering and single-sample gene-set enrichment anal. were used to divide THYM samples into different immunotypes. Differentially expressed genes (DEGs) between those immunotypes were used to do the Kyoto Encyclopedia of Genes and Genomes anal., Gene Ontol. annotations, and protein-protein interaction network. Furthermore, the survival-related DEGs were used to construct prognostic model with lasso regression. The model was verified by survival anal., receiver operating characteristic curve, and principal component anal. Furthermore, the correlation coefficients of stemness index and riskscore, tumor mutation burden (TMB) and riskscore, drug sensitivity and gene expression were calculated with Spearman method. THYM samples were divided into immunotype A and immunotype B. A total of 707 DEGs were enriched in various cancer-related or immune-related pathways. An 11-genes signature prognostic model (CELF5, ODZ1, CD1C, DRP2, PTCRA, TSHR, HKDC1, KCTD19, RFX8, UGT3A2, and PRKCG) was constructed from 177 survival-related DEGs. The prognostic model was significantly related to overall survival, clin. features, immune cells, TMB, and stemness index. The expression of some genes were significantly related to drug sensitivity. For the first time, a prognostic model of 11 genes was identified based on the immune microenvironment in patients with THYM, which may be helpful for diagnosis and prediction. The associated factors (immune microenvironment, mutation status, and stemness) may be useful for exploring the mechanisms of THYM. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Recommanded Product: 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Recommanded Product: 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies was written by Kawasaki, Natsumi;Yamashita-Kashima, Yoriko;Fujimura, Takaaki;Yoshiura, Shigeki;Harada, Naoki;Kondoh, Osamu;Yoshimura, Yasushi. And the article was included in Molecular Biology Reports in 2022.Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:

Obinutuzumab, a Type II anti-CD20 antibody, is used to treat follicular lymphoma. A major mode of action of obinutuzumab is antibody-dependent cellular cytotoxicity (ADCC). Knowledge of the mechanisms of resistance to obinutuzumab is important for the development of next-line strategies to follow obinutuzumab-containing therapy, including obinutuzumab retreatment. Unfortunately, the mechanisms by which tumor cells acquire resistance to ADCC are still poorly understood. To address this, we examined the mechanisms of resistance to obinutuzumab-induced ADCC and the combination efficacy of obinutuzumab and clin. available agents in the established resistant cells. Methods and results: We established cells resistant to obinutuzumab-induced ADCC using the non-Hodgkin lymphoma cell line RL and examined their mechanisms of resistance and the combination efficacy of obinutuzumab and clin. available agents. Comprehensive anal. by RNA sequencing of resistance mechanisms revealed that abnormal Fas signaling decreased sensitivity to ADCC in resistant clones. Combination treatment with prednisolone, a component of CHOP and CVP, was found to enhance ADCC sensitivity of RL cells and resistant clones and to significantly suppress tumor growth in xenograft models. Treatment with prednisolone upregulated expression of CD20 and an apoptosis-inducing protein BIM, which might augment perforin/granzyme B-mediated cell death. Furthermore, pretreatment of the effector cells with bendamustine enhanced ADCC activity, and treatment with obinutuzumab plus bendamustine showed significant antitumor efficacy in xenograft models. It was speculated that bendamustine upregulates ADCC activity by potentiating granules-mediated cell killing. Our study revealed a novel mechanism underlying obinutuzumab-induced ADCC resistance and indicated that ADCC resistance could be overcome by combining obinutuzumab with prednisolone or bendamustine. This study provides a scientific rationale for obinutuzumab-retreatment in combination with clin. available chemotherapeutic agents for obinutuzumab resistant follicular lymphoma. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Formula: C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Formula: C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Five Mn(II) Coordination Polymers Based on 2,3′,5,5′-Biphenyl Tetracarboxylic Acid: Syntheses, Structures, and Magnetic Properties was written by Zhao, Ying;Chang, Xin-Hong;Liu, Guang-Zhen;Ma, Lu-Fang;Wang, Li-Ya. And the article was included in Crystal Growth & Design in 2015.Category: imidazoles-derivatives The following contents are mentioned in the article:

Five manganese(II) coordination polymers with 2,3′,5,5′-biphenyl tetracarboxylic acid (H₄bptc) and five N-donor ancillary ligands, {[Mn₂(bptc)(2,2′-bipy)₂]·2H₂O}_n (1), {[Mn₂(H₂bptc)₂(phen)₄]·6H₂O} (2), {[Mn₃(Hbptc)₂(4,4′-bipy)₄(H₂O)₄]·4H₂O}_n (3), {[Mn₂(bptc)(1,4-biyb)₂]}_n (4), and {[Mn₃(Hbptc)₂(biip)₂(H₂O)₂]}_n (5) [2,2′-bipy = 2,2′-bipyridine, phen = 1,10-phenanthroline, 4,4′-bipy = 4,4′-bipyridine, 1,4-biyb = 1,4-bis(imidazol-1-ylmethyl)benzene, biip = 3,5-bis(1-imidazol)pyridine], were synthesized under hydrothermal conditions. Complexes 1–5 were structurally characterized by elemental anal., IR spectra, x-ray single-crystal diffraction, and powder X-ray diffraction (PXRD). Complex 1 exhibits a 2D layered structure with a (3,6)-connected (4³)₂(4⁶.6⁶.8³) topol. Complex 2 shows a 0D structure and further stacks via hydrogen-bonding interactions to give a 3D supramol. architecture. Complex 3 possesses a 3D structure with a 4-connected (4.6³.8²)(4⁴.6²)(4³.6³) topol. Complex 4 displays a 3D structure with a (4,5)-connected (4.5².6.7.8)(5.6⁴.7⁴.8)(4.5².6².7⁴.8) topol. Complex 5 features a 3D structure with a (4,5,6)-connected (4².6⁴)(4³.6⁷)(4².6⁸.7³.8²) topol. Magnetic susceptibility measurements indicate weak antiferromagnetic interactions between the Mn(II) ions in 1, 2, and 4. This study involved multiple reactions and reactants, such as 3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6Category: imidazoles-derivatives).

3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Category: imidazoles-derivatives

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Inhibition of Cytochrome P450 Enzyme and Drug-Drug Interaction Potential of Acid Reducing Agents Used in Management of CDK Inhibitors for Breast Cancer Chemotherapy. was written by Patil, Prajakta Harish;Jagadish, Puralae Channabasavaiah;Fatima, Fajeelath;Birangal, Sumit;Shenoy, Gurupur Gautham;Rao, Mahadev;Farooqui, Junaid;Rastogi, Himanshu;Sharma, Tarun;Pinjari, Jakir. And the article was included in Current drug metabolism in 2022.Product Details of 117976-90-6 The following contents are mentioned in the article:

BACKGROUND AND OBJECTIVE: Concurrent usage of proton pump inhibitors and their effect on survival and medication termination has been found in individuals receiving protein kinase inhibitor chemotherapy. To investigate the drug-drug interaction mechanism between CDK inhibitors and proton pump inhibitors, the in-silico docking approach was designed by applying computer simulation modules to predict the binding and inhibitory potential. METHODS: The interaction potential of proton pump inhibitors and CDK inhibitors was predicted utilising molecular docking techniques that employed Schrödinger algorithms to capture the dynamics of the CYP450 enzyme-inhibitor interaction between proton pump inhibitors and CDK inhibitors. Additionally, the human liver microsomes assay was used to determine the in vitro half-maximal inhibitory concentration (IC₅₀) of proton pump inhibitors and the inactivation of CDK inhibitors via CYP3A4. RESULTS: Proton pump inhibitors alter the conformation of the CYP3A4 and CYP2C19 enzymes and interact with the heme prosthetic group, as determined by docking studies. It may result in the suppression of CDK inhibitors’ metabolism via competitive inhibition at the binding site of an enzyme. Omeprazole and rabeprazole both significantly block midazolam’s 1′-hydroxylation by CYP3A4 in vitro, with IC₅₀ values of 9.86μM and 9.71μM, respectively. When omeprazole and rabeprazole are co-incubated in human liver microsomes at a 30μM concentration equivalent to the C_max of omeprazole and rabeprazole, rabeprazole significantly prolongs the metabolic clearance of palbociclib, whereas omeprazole affects the ribociclib CYP3A4-mediated metabolism. CONCLUSION: Using dynamic models, we determined that proton pump inhibitors such as rabeprazole and omeprazole indeed have the potential to cause clinically significant drug-drug interactions with CDK inhibitors in the treatment of estrogen receptor (ER) positive and HER2-positive breast cancer. As a result, it is suggested to use caution when prescribing proton pump inhibitors to these individuals. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Product Details of 117976-90-6).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Product Details of 117976-90-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Large Conjugated Bis/Triimidazolium Derivatives Directed Iodobismuthates(III): Syntheses, Structures, and Visible-Light-Induced Photocatalytic Properties was written by Li, Fu-Ying;Wen, Xuan;Xue, Zhen-Zhen;Pan, Jie;Wei, Qi;Wei, Li. And the article was included in Crystal Growth & Design in 2022.HPLC of Formula: 1374155-84-6 The following contents are mentioned in the article:

Under the direction of large conjugated organic species, a series of novel iodobismuthates(III), [Me₃BIP][BiI₆] (1, Me₃BIP = N,N’,N”-trimethyl-3,5-bis(imidazole-1-yl)pyridine), [Me₃BIP][Bi₂I₉] (2), [Me₃TIP][Bi₂I₉] (3, Me₃TIP = N,N’,N”-trimethyl-tris[4-(1H-imidazole-1-yl)-phenyl]amine), and [Me₃TIB][Bi₂I₉] (4, Me₃TIB = N,N’,N”-trimethyl-1,3,5-tris(1-imidazolyl)benzene), were synthesized via the solvothermal method. These iodobismuthates display two types of structures: 1 contains a [BiI₆]^3- monometallic unit, and 2–4 possess binuclear [Bi₂I₉]^3- clusters, which are formed by two BiI₆ octahedra via face-sharing. The reactants BIP, TIP, and TIB were in situ transformed into [Me₃BIP]³⁺ in 1 and 2, [Me₃TIP]³⁺ in 3, and [Me₃TIB]³⁺ in 4 through the direct N-methylation reaction. UV-visible spectra analyses imply that all compounds possess potential semiconductor properties with narrow band gaps of 2.14, 2.02, 2.09, and 2.07 eV for 1–4, resp. Compound 3 has high visible-light-driven photocatalytic degradation activity and good recyclability to organic pollutants. Radical trapping experiments combined with theor. calculations show that the conjugated organic cations contribute to the narrow band gaps of the semiconductors, which can efficiently restrain the recombination of photogenerated electron-hole pairs, resulting in a good photocatalytic efficiency and stability under visible-light irradiation It is expected that the work will shed useful insights in exploitation of novel halometallates with narrow energy gaps by employing large conjugated organic templates. This study involved multiple reactions and reactants, such as 3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6HPLC of Formula: 1374155-84-6).

3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.HPLC of Formula: 1374155-84-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients was written by Qu, Changju;Zou, Rui;Wang, Peng;Zhu, Qian;Kang, Liqing;Ping, Nana;Xia, Fan;Liu, Hailing;Kong, Danqing;Yu, Lei;Wu, Depei;Jin, Zhengming. And the article was included in Frontiers in Immunology in 2022.Computed Properties of C16H21Cl2N3O2 The following contents are mentioned in the article:

Chimeric antigen receptor T cell (CAR-T) therapy has emerged as highly effective in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but only about 40% patients have achieved sustained responses. Here, we conducted a phase II clin. trial testing efficacy and toxicities of CAR-T therapy in R/R non-Hodgkin’s lymphoma patients (NCT03196830). Among enrolled patients, 33 R/R DLBCL patients pretreated with DFC (decitabine, fludarabine plus cyclophosphamide) lymphodepletion chemotherapy and infused with tandem CD19-CD22 based CAR-T cells were drawn out for efficacy and toxicities of CAR-T therapy evaluation. With a median follow-up of 10.9(0.6-29.0) months, the best overall response and complete remission (CR) rates were 90.9% and 63.6%, resp. The median progression-free survival (PFS) was 10.2 mo and overall survival (OS) was undefined. The 2- year OS and PFS rates were 54.3% and 47.2%, resp. No severe grade 4 cytokine release syndrome (CRS) was observed and grade 3 CRS was observed in only 7 patients; 3 patients developed mild immune effect or cell-associated neurotoxic syndrome. All toxicities were transient and reversible and no CART-related mortality. Further subgroup anal. showed that achieving CR was an independent prognostic factor associated with favorable PFS and OS. The 2- year OS and PFS for patients who achieved CR within 3 mo (undefined vs. undefined P = 0.021 and undefined vs. undefined P = 0.036) or during the follow-up period were significantly longer than those who did not (undefined vs. 4.6 mo P < 0.0001 and undefined vs. 2.0months P<0.001). While severe CRS was also an independent prognostic factor but associated with inferior PFS and OS. The 2-yr OS and PFS for patients with grade 3 CRS were significantly shorter than those with grade 0-2 CRS (4.1 mo vs. undefined P<0.0001 and 1.7 mo vs. undefined P = 0.0002). This study indicated that CD19/CD22 dual-targeted CAR-T therapy under a decitabine-containing lymphodepletion regimen may be a safe, potent effective approach to R/R DLBCL patients. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Computed Properties of C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Computed Properties of C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem